Amlodipine/valsartan

Amlodipine/valsartan is a blood pressure lowering combination drug. It contains amlodipine, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin receptor blocker.[2] This combination is usually well tolerated and effective for the reduction of blood pressure.[3]

Amlodipine/valsartan
Combination of
AmlodipineCalcium channel blocker
ValsartanAngiotensin II receptor antagonist
Clinical data
Trade namesExforge
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
CompTox Dashboard (EPA)
  (verify)

The combination was patented by Novartis Pharmaceuticals and sold under the brand name Exforge. The patent expired in September 2012.[4]

Amlodipine/valsartan is available in different dose preparations: 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10/320 mg of amlodipine and valsartan, respectively.[5]

The combination is also available with included hydrochlorothiazide, for patients who need a three-drug regimen to manage their blood pressure.[6]

References

  1. "Amlodipine / valsartan (Exforge) Use During Pregnancy". Drugs.com. 11 July 2019. Retrieved 13 February 2020.
  2. "Valsartan Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
  3. Eckert S, Freytag SB, Müller A, Klebs SH (September 2013). "Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors". Blood Pressure. 22 (sup1): 11–21. doi:10.3109/08037051.2013.793891. PMID 23713686. S2CID 25814898.
  4. "Generic Exforge HCT". Blood-pressure.emedtv.com. Retrieved 2012-03-05.
  5. "Exforge- amlodipine besylate and valsartan tablet, film coated". DailyMed. 12 June 2019. Retrieved 12 February 2020.
  6. "Exforge HCT- amlodipine valsartan and hydrochlorothiazide tablet, film coated". DailyMed. Retrieved 12 February 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.